UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 569

Sortiert nach

Toward a Functional Cure for Hepatitis B

Gut and liver, 2024-07, Vol.18 (4), p.593-601

Lok, Anna S F

2024

Link zum Volltext

Verfügbarkeit prüfen

Hepatitis B surface antigen seroclearance: Immune mechanisms, clinical impact, importance for drug development

Journal of hepatology, 2020-08, Vol.73 (2), p.409-422

2020

Link zum Volltext

Verfügbarkeit prüfen

Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China

Gastroenterology (New York, N.Y. 1943), 2020-01, Vol.158 (1), p.215-225.e6

2020

Link zum Volltext

Verfügbarkeit prüfen

Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients

Journal of hepatology, 2018-01, Vol.68 (1), p.16-24

2018

Link zum Volltext

Verfügbarkeit prüfen

Association of Serum Hepatitis B Virus RNA With Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Under Nucleos(t)ide Analogues Therapy

The Journal of infectious diseases, 2022-09, Vol.226 (5), p.881-890

2022

Link zum Volltext

Verfügbarkeit prüfen

Management of Hepatitis‐B Virus Infection in Immunocompromised Children

Journal of pediatric gastroenterology and nutrition, 2021-04, Vol.72 (4), p.597-602

2021

Link zum Volltext

Verfügbarkeit prüfen

Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B

Journal of hepatology, 2018-08, Vol.69 (2), p.278-285

2018

Link zum Volltext

Verfügbarkeit prüfen

Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low‐level viraemia

Liver international, 2021-06, Vol.41 (6), p.1254-1264

2021

Link zum Volltext

Verfügbarkeit prüfen

Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B

The Journal of infectious diseases, 2016-11, Vol.214 (10), p.1492-1497

2016

Link zum Volltext

Verfügbarkeit prüfen

Is there any need for new, long-acting nucleos(t)ide analogues for the treatment of hepatitis B infection?

Journal of hepatology, 2021-05, Vol.74 (5), p.1011-1014

2021

Link zum Volltext

Verfügbarkeit prüfen

Real‐world study on HBsAg loss of combination therapy in HBeAg‐negative chronic hepatitis B patients

Journal of viral hepatitis, 2022-09, Vol.29 (9), p.765-776

2022

Link zum Volltext

Verfügbarkeit prüfen

Management of Hepatitis-B Virus Infection in Immunocompromised Children: A Single Center Experience

Journal of pediatric gastroenterology and nutrition, 2021-04, Vol.72 (4), p.597-602

2021

Link zum Volltext

Verfügbarkeit prüfen

Evidence of Residual Ongoing Viral Replication in Chronic Hepatitis B Patients Successfully Treated With Nucleos(t)ide Analogues

The Journal of infectious diseases, 2023-03, Vol.227 (5), p.675-685

2023

Link zum Volltext

Verfügbarkeit prüfen

Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide

Digestive and liver disease, 2020-10, Vol.52 (10), p.1164-1169

2020

Link zum Volltext

Verfügbarkeit prüfen

Lamivudine: fading into the mists of time

Clinical and molecular hepatology, 2017-12, Vol.23 (4), p.314

2017

Link zum Volltext

Verfügbarkeit prüfen

Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapy

Journal of hepatology, 2012-08, Vol.57 (2), p.442-450

2012

Link zum Volltext

Verfügbarkeit prüfen

Hepatitis B surface antigen kinetics after discontinuation of and retreatment with oral antivirals in non‐cirrhotic HBeAg‐positive chronic hepatitis B

Journal of viral hepatitis, 2021-08, Vol.28 (8), p.1121-1129

2021

Link zum Volltext

Verfügbarkeit prüfen

Management of chronic hepatitis B infection: Current treatment guidelines, challenges, and new developments

World journal of gastroenterology : WJG, 2014-05, Vol.20 (20), p.6262-6278

2014

Link zum Volltext

Verfügbarkeit prüfen

Albumin-bilirubin score is associated with response to pegylated interferon and nucleos(t)ide analogues in chronic hepatitis B patients

Clinica chimica acta, 2020-03, Vol.502, p.120-127

2020

Link zum Volltext

Verfügbarkeit prüfen

Expanding indications for chronic hepatitis B treatment: Is it really desirable to treat everyone?

World journal of gastroenterology : WJG, 2024-05, Vol.30 (17), p.2294-2297

2024

Link zum Volltext

Verfügbarkeit prüfen

Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patients

Medicine (Baltimore), 2021-07, Vol.100 (28), p.e26571-e26571

2021

Link zum Volltext

Verfügbarkeit prüfen

HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct‐acting antivirals

Journal of viral hepatitis, 2018-01, Vol.25 (1), p.72-79

2018

Link zum Volltext

Verfügbarkeit prüfen

Effect of nucleos(t)ide analogues on blood lipid profiles in patients with chronic hepatitis B: A cross-sectional survey

Medicine (Baltimore), 2022-12, Vol.101 (50), p.e31980

2022

Link zum Volltext

Verfügbarkeit prüfen

Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a

Journal of hepatology, 2012-05, Vol.56 (5), p.1006-1011

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 569

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(477)
Mit Volltextzugriff
(542)

Publikationsform

Sprache

6 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(465)
Science & Technology
(465)
Humans
(303)
Hepatitis B Virus
(246)
Gastroenterology & Hepatology
(242)
Nucleoside Analogues
(219)
Hepatitis B
(215)
Hepatitis B, Chronic - Drug Therapy
(206)
Antiviral Agents - Therapeutic Use
(205)
Chronic Hepatitis B
(189)
Hepatitis
(136)
Male
(129)
Treatment Outcome
(128)
Female
(127)
Interferon
(124)
Adult
(121)
Nucleoside Analogue
(119)
Nucleoside Analogs
(115)
Middle Aged
(114)
Hepatocellular Carcinoma
(113)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Toward a Functional Cure for Hepatitis B

Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference

Hepatitis B surface antigen seroclearance: Immune mechanisms, clinical impact, importance for drug development

Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China

Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients

Association of Serum Hepatitis B Virus RNA With Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Under Nucleos(t)ide Analogues Therapy

Management of Hepatitis‐B Virus Infection in Immunocompromised Children

Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B

Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low‐level viraemia

Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B

Is there any need for new, long-acting nucleos(t)ide analogues for the treatment of hepatitis B infection?

Real‐world study on HBsAg loss of combination therapy in HBeAg‐negative chronic hepatitis B patients

Management of Hepatitis-B Virus Infection in Immunocompromised Children: A Single Center Experience

Evidence of Residual Ongoing Viral Replication in Chronic Hepatitis B Patients Successfully Treated With Nucleos(t)ide Analogues

Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide

Lamivudine: fading into the mists of time

Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapy

Hepatitis B surface antigen kinetics after discontinuation of and retreatment with oral antivirals in non‐cirrhotic HBeAg‐positive chronic hepatitis B

Management of chronic hepatitis B infection: Current treatment guidelines, challenges, and new developments

Albumin-bilirubin score is associated with response to pegylated interferon and nucleos(t)ide analogues in chronic hepatitis B patients

Expanding indications for chronic hepatitis B treatment: Is it really desirable to treat everyone?

Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patients

HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct‐acting antivirals

Effect of nucleos(t)ide analogues on blood lipid profiles in patients with chronic hepatitis B: A cross-sectional survey

Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a

Suchergebnisse filtern